Xyntha (Antihemophilic factor [recombinant]) for Hemophilia

Overview
Xyntha is approved by the Food and Drug Administration (FDA) to control and prevent bleeding episodes in children and adults with hemophilia A. Xyntha can also be used for perioperative (before, during, and after surgery) care. The technical name of Xyntha is Antihemophilic factor (recombinant).

Xyntha is a clotting factor. Clotting factors work by supplying proteins missing in people with hemophilia.

How do I take it?
Prescribing information states that Xyntha is given as an intravenous injection.

Xyntha comes as a powder that must be reconstituted before injection.

Side effects
The FDA-approved label for Xyntha lists common side effects including headache, joint pain, fever, and cough.

Rare but serious side effects listed for Xyntha include systemic allergic reactions and the development of inhibitors.

For more details about this treatment, visit:

Xyntha.com

Treatment of Hemophilia – Hemophilia Federation of America